EMD Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer

First patient dosed in tecemotide Phase III trial; study recruiting across 250 sites in over 20 countries START2 builds upon the data from the START* trial and explores the potential of tecemotide in patients with Stage III NSCLC who have demonstrated stable disease or objective response after concurrent chemoradiotherapy April 7, 2014 EMD Serono, Inc., a subsidiary of Merck KGaA, …